Delivering bad news to patients

Thursday, October 24, 2019

Strategies and guidelines for delivering bad news to patients from David Henry, MD, and Ilana Yurkiewicz, MD.

Timestamps:

  • This week in Oncology (01:30)
  • Conversation (04:22)

This week, the host of Blood & Cancer and the writer, producer, and talent behind the Clinical Correlation segment sit down together for the first time ever.

Dr. Henry and Dr. Yurkiewicz share strategies and anecdotes about their experiences learning how to give patients terrible news and --perhaps more importantly -- how not to.

Links:

This week in Oncology.

Immunotherapy enables nephrectomy with good outcomes in advanced RCC
by Susan London

Some patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors can safely undergo nephrectomy and experience favorable surgical outcomes and pathologic responses according to a cohort study from Urologic Oncology.

SOURCE: Singla N et al. Urol Oncol. 2019 Sep 12. doi: 10.1016/j.urolonc.2019.08.012

For more MDedge podcasts, go to mdedge.com/podcasts

Email the show: [email protected]

Interact with us on Twitter @mdedgehemonc

David Henry on Twitter @davidhenrymd

Ilana Yurkiewicz on Twitter @ilanayurkiewicz

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.